CytoMed Reports Increased Net Loss and Rapid Cash Burn Amidst Clinical Progress and Strategic Expansion

summarizeSummary

CytoMed Therapeutics reported a significant increase in its net loss and a substantial reduction in cash balances for the full year 2025, which underpins the going concern warning disclosed in its concurrently filed 20-F. The company's cash position of US$1.63 million against a burn rate of over US$2 million raises immediate concerns about its financial runway. While the advancement of clinical trials and strategic acquisitions are positive developments for the long-term, the severe financial deterioration presents a critical challenge for the company's near-term viability. Investors should closely monitor the company's ability to secure additional funding to support its operations and ongoing clinical programs.

check_boxKey Events

• Increased Net Loss

  The company's audited net loss for the financial year ended December 31, 2025, increased to US$3.11 million, up from US$1.96 million in 2024.

• Significant Cash Burn

  Cash and bank balances decreased substantially to US$1.63 million as of December 31, 2025, from US$3.87 million in 2024, indicating a rapid depletion of liquidity.

• Clinical Trial Advancement

  The ANGELICA CAR-T Phase I clinical trial in Singapore has proceeded to dose level 2 and is soon escalating to the final dose level 3, with target completion by year-end.

• Strategic Expansion and Research Validation

  CytoMed entered an MOU for a new Phase I clinical trial in Malaysia, acquired a Malaysian cord blood bank, and co-authored a preclinical study with MD Anderson Cancer Center suggesting potential for its allogeneic γδ T cell therapy in treating AML.

auto_awesomeAnalysis

CytoMed Therapeutics reported a significant increase in its net loss and a substantial reduction in cash balances for the full year 2025, which underpins the going concern warning disclosed in its concurrently filed 20-F. The company's cash position of US$1.63 million against a burn rate of over US$2 million raises immediate concerns about its financial runway. While the advancement of clinical trials and strategic acquisitions are positive developments for the long-term, the severe financial deterioration presents a critical challenge for the company's near-term viability. Investors should closely monitor the company's ability to secure additional funding to support its operations and ongoing clinical programs.